Skip to main content

Table 3 Comparison of patient-reported outcomes between the groups according to clinical disease activity level

From: Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation

  Remission/low disease activitya Moderate-to-high disease activitya
Measure Concordant group
(n = 10)
Discordant group
(n = 28)
P value Concordant group
(n = 10)
Discordant group
(n = 18)
P value
Pain VAS 18.5
(3.0–26.0)
37.0
(24.0–56.0)
.006 36.0
(14.0–50.0)
66.0
(56.0–74.0)
.02
HAQ-II 0.2
(0.0–0.3)
0.9
(0.5–1.2)
.001 0.9
(0.4–1.2)
1.2
(0.7–1.2)
.10
SF-MPQ-2 0.7
(0.3–1.6)
1.4
(0.8–2.6)
.10 1.9
(1.0–2.7)
2.3
(1.8–3.9)
.18
WPI 5.0
(1.0–8.0)
6.0
(4.0–9.0)
.18 4.0
(3.0–7.0)
8.0
(6.0–10.0)
.005
SS score 2.5
(1.0–4.0)
4.0
(3.0–6.0)
.11 4.0
(2.0–6.0)
6.0
(3.0–8.0)
.16
PSD 8.0
(2.0–12.0)
9.0
(8.0–15.0)
.13 7.5
(6.0–13.0)
13.5
(10.0–16.0)
.01
BRAF score 4.5
(3.7–5.3)
5.2
(4.3–6.3)
.23 5.0
(4.0–6.0)
6.3
(4.3–7.0)
.28
PROMIS
 Pain interference 1.3
(1.1–1.8)
1.9
(1.5–2.4)
.05 2.2
(1.6–2.8)
2.9
(2.1–3.5)
.05
 Ability to participate 4.3
(3.8–5.0)
3.5
(3.1–4.2)
.02 3.7
(3.1–4.0)
3.3
(2.6–4.0)
.43
 Sleep disturbance 1.6
(1.3–2.3)
2.1
(1.8–2.9)
.06 2.3
(1.9–2.8)
2.5
(1.8–3.3)
.50
 Fatigue 1.8
(1.0–3.4)
2.6
(2.0–3.5)
.10 2.9
(2.3–3.4)
3.1
(2.3–3.8)
.43
MAAS 5.0
(4.5–5.6)
5.1
(4.6–5.4)
.95 4.4
(4.1–4.9)
5.3
(4.5–5.5)
.07
PHQ-9 1.0
(0.0–5.0)
4.0
(2.0–6.0)
.04 4.0
(2.0–11.0)
4.0
(3.0–6.0)
>.99
GAD-7 0.0
(0.0–1.0)
1.0
(0.0–3.0)
.06 1.5
(0.0–4.0)
1.5
(1.0–6.0)
.71
  1. Values are presented as median (interquartile range)
  2. aDisease activity level was classified according to the Clinical Disease Activity Index
  3. BRAF Bristol Rheumatoid Arthritis Fatigue, FRS Fibromyalgia Research Survey, GAD-7 Generalized Anxiety Disorder 7, HAQ-II Health Assessment Questionnaire II, MAAS Mindful Attention Awareness Scale, PHQ-9 Patient Health Questionnaire 9, PROMIS Patient-Reported Outcomes Measurement Information System, PSD polysymptomatic distress, SF-MPQ-2 Short-Form McGill Pain Questionnaire 2, SS Symptom Severity, VAS visual analog score, WPI Widespread Pain Index